Crossmark

Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial

Crossref DOI link: https://doi.org/10.1186/s12888-024-05502-y

Published Online: 2024-01-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vanderijst, Laetitia

Hever, Felix

Buot, Anne

Dauré, Charles

Benoit, Janaïna

Hanak, Catherine

Veeser, Johannes

Morgiève, Margot

Campanella, Salvatore

Kornreich, Charles

Mallet, Luc

Leys, Christophe

Noël, Xavier
Funding

Funding for this research was provided by:

Fonds De La Recherche Scientifique - FNRS (40010687)

Fonds Iris-Recherche (2023-J1820690-232470, 2023-J1820690-232470)

Brugmann Foundation (2022-10, 2022-10)
License Information

Text and Data Mining valid from 2024-01-26

Version of Record valid from 2024-01-26
More Information

Article History

Received: 2 January 2024

Accepted: 6 January 2024

First Online: 26 January 2024

Declarations

:

: The project is approved by the Hospital Ethics Committee of the Brugmann University Hospital (reference number: CE 2023/09). Consent to participate must be obtained before the screening procedure can begin. Prior to signing the informed consent form, all potential participants will be provided with comprehensive oral and written information about the trial, including potential risks associated with the investigational medicinal product. Close family members will have the possibility to meet one of the investigators to receive information about the trial and ask questions.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below